

## **Global Respiratory Inhalers Market Report and Forecast 2024-2032**

Market Report (7 Days) | 2024-04-19 | 140 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$4999.00
- Five User License \$5999.00
- Corporate License \$6999.00

### **Report description:**

Global Respiratory Inhalers Market Report and Forecast 2024-2032

The global respiratory inhalers market size was valued at USD 33.5 billion in 2023. It is expected to grow at a CAGR of 6.80% during the forecast period of 2024-2032, driven by rising incidence of asthma, COPD, and other respiratory conditions globally. The market is experiencing robust growth and is expected to reach USD 59.93 billion by 2032.

Global Respiratory Inhalers Market Analysis

Respiratory inhalers are medical devices used to deliver medication directly to the lungs in the treatment of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. The market for these devices is expanding due to rising awareness about respiratory health and the need for effective treatment options.

Market Drivers

- ☐ Increasing Prevalence of Respiratory Diseases: The rising incidence of asthma, COPD, and other respiratory conditions worldwide is a primary driver for the demand for respiratory inhalers.
- ☐ Technological Advancements: Innovations in inhaler devices, such as the development of smart inhalers with digital monitoring capabilities, are enhancing patient adherence and treatment outcomes.
- ☐ Growing Awareness and Healthcare Expenditure: Increased awareness about respiratory health and higher healthcare spending are contributing to the market's growth.
- ☐ Aging Population: The growing elderly population, which is more susceptible to respiratory diseases, is further driving the demand for inhalers.

Market Restraints

- ☐ High Cost of Advanced Inhalers: The elevated price of technologically advanced inhalers can limit their accessibility, particularly in low- and middle-income countries.
- ☐ Environmental Concerns: The environmental impact of certain inhaler propellants, particularly in metered-dose inhalers, poses a challenge to market growth.
- ☐ Regulatory Hurdles: Stringent regulatory requirements for the approval of medical devices can delay the introduction of new inhalers to the market.

Market Opportunities

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- ☐Personalized Medicine: The trend towards personalized medicine offers opportunities for the development of inhalers tailored to individual patient needs.
- ☐Emerging Markets: Expanding healthcare infrastructure and increasing awareness in emerging economies present significant growth opportunities.
- ☐Digital Health Integration: The integration of digital health technologies with inhalers provides opportunities for improved patient monitoring and adherence.
- ☐Eco-friendly Inhalers: There is a growing demand for environmentally sustainable inhalers, opening avenues for innovation in this area.

#### Market Challenges

- ☐Adherence and Compliance: Ensuring patient adherence to inhaler use and proper inhalation techniques remains a challenge.
- ☐Competition and Pricing Pressure: Intense competition among market players can lead to pricing pressures, impacting profitability.
- ☐Access and Affordability: Ensuring access to inhalers, particularly in low-resource settings, and addressing affordability issues are ongoing challenges.

#### Global Respiratory Inhalers Market Outlook

The global respiratory inhalers market is expected to grow at a significant CAGR during the forecast period. The market's growth prospects are promising due to the ongoing advancements in inhaler technologies and the increasing focus on improving patient adherence and outcomes.

The global respiratory inhalers market is poised for significant growth, driven by the rising burden of respiratory diseases and technological innovations in inhalation therapy. The market presents opportunities for companies to innovate and expand their product portfolios to meet the evolving needs of patients and healthcare providers.

#### Global Respiratory Inhalers Market Trends

The global respiratory inhalers market is undergoing significant transformations, driven by technological advancements, an increase in respiratory disorders, and a greater emphasis on healthcare management. This sector's evolution is marked by several key trends that are shaping its current state and future trajectory.

##### -☐Technological Innovation and Smart Inhalers

A prominent trend is the rise of digital health technologies, including smart inhalers equipped with sensors and Bluetooth capabilities. These devices track medication usage, monitor patient adherence, and can transmit data to healthcare providers, enabling personalized treatment plans and improving patient outcomes. The integration of digital tools into respiratory care is expected to expand, driven by the demand for more effective disease management and treatment optimization.

##### -☐Rising Prevalence of Respiratory Diseases

The global burden of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis is increasing, fueled by factors like air pollution, smoking, and changing lifestyles. This surge is driving the demand for respiratory inhalers, with a particular emphasis on advanced, user-friendly devices that can provide efficient drug delivery and ease of use for patients of all ages.

##### -☐Focus on Combination Therapies

There is a growing inclination towards combination therapies, where two or more active ingredients are delivered through a single inhaler. This approach simplifies treatment regimens, improves patient compliance, and has been found to be more effective for certain conditions, such as COPD. The development and approval of combination inhalers are accelerating, indicating a shift in treatment paradigms.

##### -☐Environmental Considerations and Sustainable Solutions

The environmental impact of inhalers, especially metered-dose inhalers (MDIs) containing hydrofluoroalkanes (HFAs) as propellants, is a growing concern. This has led to increased research into and demand for eco-friendly alternatives, such as dry powder inhalers (DPIs) and soft mist inhalers (SMIs), which have a lower environmental footprint. Regulatory bodies and manufacturers are focusing on sustainable inhaler solutions to mitigate climate change impacts.

##### -☐Expansion in Emerging Markets

Emerging economies present significant growth opportunities for the respiratory inhalers market, driven by increasing healthcare

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

expenditures, growing awareness of respiratory diseases, and improving healthcare infrastructure. Companies are expanding their presence in these regions, tailoring products to meet specific market needs and navigating regulatory landscapes.

#### -□Regulatory and Reimbursement Challenges

Navigating the complex regulatory environment remains a challenge for inhaler manufacturers, with stringent approval processes for new devices and therapies. Additionally, reimbursement policies influence the adoption and accessibility of advanced inhalers, impacting market dynamics and patient access to innovative treatments.

In conclusion, the global respiratory inhalers market is at a pivotal juncture, with technological innovation, the rising burden of respiratory diseases, and environmental considerations steering its growth. As the market continues to evolve, stakeholders, including manufacturers, healthcare providers, and regulatory bodies, must adapt to these trends to meet the changing needs and expectations of patients and to ensure the delivery of efficient, sustainable, and accessible respiratory care solutions.

#### Global Respiratory Inhalers Market Segmentation

##### Market Breakup by Product□□

##### -□Dry Powder Inhalers□□□□□□

##### -□Metered Dosed Inhalers

##### -□Soft Mist Inhalers

##### -□Nebulizers

##### o□Jet Nebulizers

##### o□Ultrasonic Nebulizers□

##### o□Mesh Nebulizers□

The global respiratory inhalers market, segmented by product into Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Soft Mist Inhalers (SMIs), and Nebulizers (including Jet, Ultrasonic, and Mesh Nebulizers), is experiencing substantial growth, driven by the rising prevalence of respiratory diseases and technological advancements. DPIs are gaining popularity for their environmental benefits and ease of use, while MDIs remain essential due to their affordability and widespread availability. SMIs offer precise dosing and are becoming more common in treatment regimens.

Nebulizers, particularly mesh nebulizers, are witnessing increased demand for their efficiency and portability, catering especially to pediatric and elderly patients. The market is poised for significant expansion, with innovation and patient adherence being key drivers. This diverse product range ensures comprehensive coverage across different patient needs and preferences, positioning the respiratory inhalers market for robust growth in the forecast period.

##### Market Breakup by Type

##### -□Conventional Inhalers□□

##### -□Smart Inhalers

The respiratory inhalers market is bifurcated into Conventional Inhalers and Smart Inhalers, each serving pivotal roles in respiratory disease management. Conventional inhalers, encompassing a wide array of DPIs, MDIs, and others, have long been the backbone of asthma and COPD treatment due to their accessibility and proven effectiveness. However, the advent of Smart Inhalers, equipped with digital technology for tracking usage, providing feedback, and enhancing patient adherence through connectivity with healthcare providers, represents a significant market shift.

Driven by the increasing burden of respiratory diseases and the demand for personalized healthcare solutions, Smart Inhalers are poised for substantial growth. Their ability to improve treatment outcomes and patient engagement is expected to make them a key driver in the market's future expansion. As healthcare continues to evolve towards more integrated and intelligent solutions, Smart Inhalers are set to redefine respiratory care, signaling a new era of innovation and patient-centric management.

##### Market Breakup by Indication

##### -□Asthma□□□

##### -□COPD□

The respiratory inhalers market, when segmented by indication, focuses primarily on Asthma and Chronic Obstructive Pulmonary Disease (COPD), two of the most prevalent respiratory conditions globally. Asthma, characterized by chronic inflammation of the airways, requires a range of inhalers for both maintenance and rescue medication, driving a substantial portion of the market demand. COPD, a progressive lung disease often resulting from long-term exposure to irritating gases or particulate matter, has a

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

growing patient population necessitating advanced inhaler solutions for effective disease management.

Both segments are key drivers of the market due to the rising incidence of these conditions, attributed to factors such as air pollution, smoking, and genetic predisposition. The demand for innovative, patient-friendly inhalation devices is increasing, with a particular emphasis on devices that offer improved drug delivery, adherence, and monitoring capabilities. The future growth of the respiratory inhalers market is significantly influenced by the ongoing development of treatments tailored to the unique needs of asthma and COPD patients, highlighting the critical role these indications play in shaping market dynamics.

#### Market Breakup by End-user

- Hospitals
- Clinics
- Homecare Settings
- Others□

The respiratory inhalers market segmentation by end-user includes hospitals, clinics, homecare settings, and others, each playing a critical role in the distribution and accessibility of inhalation therapy devices. Hospitals are a primary channel for the prescription and initial administration of inhalers, especially in acute cases, and for patient education on correct usage. This segment is crucial for introducing new inhalation technologies and devices to patients and healthcare professionals.

The "Others" category encompasses online retailers, home care settings, and clinics, which have seen growth due to the increasing preference for home-based care and the convenience of online shopping. This diversification in distribution channels ensures a wide reach, catering to varied patient preferences and needs.

As the market continues to evolve, the role of pharmacies and alternative distribution channels is expected to expand, driven by the rising demand for self-management of respiratory conditions and the availability of smart inhalers that support remote monitoring and data sharing with healthcare providers.

#### Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

The global respiratory inhalers market exhibits varied growth dynamics across regions, influenced by healthcare infrastructure, disease prevalence, and technological adoption. North America leads, propelled by advanced healthcare, high disease awareness, and innovation adoption. Europe follows, with robust healthcare systems and strong R&D support. The Asia Pacific is the fastest growing, driven by large populations, increasing healthcare investments, and rising disease awareness. Latin America and the Middle East and Africa are emerging markets, showing growth potential amid challenges like uneven healthcare access. Each region's unique factors shape its market contribution, highlighting diverse opportunities for expansion in the respiratory inhalers sector.

#### Global Respiratory Inhalers Market Competitive Landscape

The competitive landscape of the global respiratory inhalers market is characterized by the presence of leading pharmaceutical and medical device companies, each contributing to the sector's growth through innovation, research, and strategic expansions. Key players include Novartis AG, AstraZeneca, GSK plc, Chiesi Farmaceutici SpA, Lupin, Teva Pharmaceutical Industries Ltd., OMRON Corporation, Koninklijke Philips N.V., PARI GmbH, Boehringer Ingelheim International GmbH, GLENMARK PHARMACEUTICALS, Presspart Verwaltungs GmbH, Rossmax International Ltd, HELTMAN Medikal A.S., and Microlife Corporation.

#### Key Questions Answered in the Report

- What is the current and future performance of the global respiratory inhalers market?
- What is driving the demand for respiratory inhalers globally?
- What environmental concerns are affecting the respiratory inhalers market?
- What opportunities and challenges exist in the respiratory inhalers market?
- How is the integration of digital health technologies impacting the respiratory inhalers market?
- What type of products are available in the market?

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Which nebulizer type is poised to lead the segment in coming years?
- How is the global respiratory inhalers market segmented by indication, and what are the growth drivers for each segment?
- What is the market breakup based on end users?
- How are smart inhalers poised to influence the future growth of the respiratory inhalers market?
- What are the main players/companies in the market?

#### Key Benefits for Stakeholders

- The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global respiratory inhalers market from 2017-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the global respiratory inhalers market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the global respiratory inhalers industry and its attractiveness.
- The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

#### Table of Contents:

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope
  - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Respiratory Inhalers Market Overview
  - 3.1 Global Respiratory Inhalers Market Historical Value (2017-2023)
  - 3.2 Global Respiratory Inhalers Market Forecast Value (2024-2032)
- 4 Global Respiratory Inhalers Market Landscape\*
  - 4.1 Global Respiratory Inhalers Market: Developers Landscape
    - 4.1.1 Analysis by Year of Establishment
    - 4.1.2 Analysis by Company Size
    - 4.1.3 Analysis by Region
  - 4.2 Global Respiratory Inhalers Market: Product Landscape
    - 4.2.1 Analysis by Product
    - 4.2.2 Analysis by Type
    - 4.2.3 Analysis by Technology
    - 4.2.4 Analysis by Applications
- 5 Global Respiratory Inhalers Market Dynamics
  - 5.1 Market Drivers and Constraints
  - 5.2 SWOT Analysis
    - 5.2.1 Strengths
    - 5.2.2 Weaknesses
    - 5.2.3 Opportunities
    - 5.2.4 Threats
  - 5.3 Porter's Five Forces Model
    - 5.3.1 Bargaining Power of Suppliers

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Respiratory Inhalers Market Segmentation (2017-2032)
  - 6.1 Global Respiratory Inhalers Market (2017-2032) by Product
    - 6.1.1 Market Overview
    - 6.1.2 Dry Powder Inhalers
    - 6.1.3 Metered Dosed Inhalers
    - 6.1.4 Soft Mist Inhalers
    - 6.1.5 Nebulizers
      - 6.1.5.1 Jet Nebulizers
      - 6.1.5.2 Ultrasonic Nebulizers
      - 6.1.5.3 Mesh Nebulizers
  - 6.2 Global Respiratory Inhalers Market (2017-2032) by Type
    - 6.2.1 Market Overview
    - 6.2.2 Conventional Inhalers
    - 6.2.3 Smart Inhalers
  - 6.3 Global Respiratory Inhalers Market (2017-2032) by Indication
    - 6.3.1 Market Overview
    - 6.3.2 Asthma
    - 6.3.3 COPD
  - 6.4 Global Respiratory Inhalers Market (2017-2032) by End User
    - 6.4.1 Market Overview
    - 6.4.2 Hospitals
    - 6.4.3 Clinics
    - 6.4.4 Homecare Settings
    - 6.4.5 Others
  - 6.5 Global Respiratory Inhalers Market (2017-2032) by Region
    - 6.5.1 Market Overview
    - 6.5.2 North America
    - 6.5.3 Europe
    - 6.5.4 Asia Pacific
    - 6.5.5 Latin America
    - 6.5.6 Middle East and Africa
- 7 North America Respiratory Inhalers Market (2017-2032)
  - 7.1 North America Respiratory Inhalers Market (2017-2032) by Product
    - 7.1.1 Market Overview
    - 7.1.2 Dry Powder Inhalers
    - 7.1.3 Metered Dosed Inhalers
    - 7.1.4 Soft Mist Inhalers
    - 7.1.5 Nebulizers
      - 7.1.5.1 Jet Nebulizers

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 7.1.5.2 Ultrasonic Nebulizers
    - 7.1.5.3 Mesh Nebulizers
  - 7.2 North America Respiratory Inhalers Market (2017-2032) by Type
    - 7.2.1 Conventional Inhalers
    - 7.2.2 Smart Inhalers
  - 7.3 North America Respiratory Inhalers Market (2017-2032) by Country
    - 7.3.1 United States of America
    - 7.3.2 Canada
- 8 Europe Respiratory Inhalers Market (2017-2032)
  - 8.1 Europe Respiratory Inhalers Market (2017-2032) by Product
    - 8.1.1 Market Overview
    - 8.1.2 Dry Powder Inhalers
    - 8.1.3 Metered Dosed Inhalers
    - 8.1.4 Soft Mist Inhalers
    - 8.1.5 Nebulizers
      - 8.1.5.1 Jet Nebulizers
      - 8.1.5.2 Ultrasonic Nebulizers
      - 8.1.5.3 Mesh Nebulizers
  - 8.2 Europe Respiratory Inhalers Market (2017-2032) by Type
    - 8.2.1 Conventional Inhalers
    - 8.2.2 Smart Inhalers
  - 8.3 Europe Respiratory Inhalers Market (2017-2032) by Country
    - 8.3.1 United Kingdom
    - 8.3.2 Germany
    - 8.3.3 France
    - 8.3.4 Italy
    - 8.3.5 Others
- 9 Asia Pacific Respiratory Inhalers Market (2017-2032)
  - 9.1 Asia Pacific Respiratory Inhalers Market (2017-2032) by Product
    - 9.1.1 Market Overview
    - 9.1.2 Dry Powder Inhalers
    - 9.1.3 Metered Dosed Inhalers
    - 9.1.4 Soft Mist Inhalers
    - 9.1.5 Nebulizers
      - 9.1.5.1 Jet Nebulizers
      - 9.1.5.2 Ultrasonic Nebulizers
      - 9.1.5.3 Mesh Nebulizers
  - 9.2 Asia Pacific Respiratory Inhalers Market (2017-2032) by Type
    - 9.2.1 Conventional Inhalers
    - 9.2.2 Smart Inhalers
  - 9.3 Asia Pacific Respiratory Inhalers Market (2017-2032) by Country
    - 9.3.1 China
    - 9.3.2 Japan
    - 9.3.3 India
    - 9.3.4 ASEAN
    - 9.3.5 Australia
    - 9.3.6 Others

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10 Latin America Respiratory Inhalers Market (2017-2032)
  - 10.1 Latin America Respiratory Inhalers Market (2017-2032) by Product
    - 10.1.1 Market Overview
    - 10.1.2 Dry Powder Inhalers
    - 10.1.3 Metered Dosed Inhalers
    - 10.1.4 Soft Mist Inhalers
    - 10.1.5 Nebulizers
      - 10.1.5.1 Jet Nebulizers
      - 10.1.5.2 Ultrasonic Nebulizers
      - 10.1.5.3 Mesh Nebulizers
  - 10.2 Latin America Respiratory Inhalers Market (2017-2032) by Type
    - 10.2.1 Conventional Inhalers
    - 10.2.2 Smart Inhalers
  - 10.3 Latin America Respiratory Inhalers Market (2017-2032) by Country
    - 10.3.1 Brazil
    - 10.3.2 Argentina
    - 10.3.3 Mexico
    - 10.3.4 Others
- 11 Middle East and Africa Respiratory Inhalers Market (2017-2032)
  - 11.1 Middle East and Africa Respiratory Inhalers Market (2017-2032) by Product
    - 11.1.1 Market Overview
    - 11.1.2 Dry Powder Inhalers
    - 11.1.3 Metered Dosed Inhalers
    - 11.1.4 Soft Mist Inhalers
    - 11.1.5 Nebulizers
      - 11.1.5.1 Jet Nebulizers
      - 11.1.5.2 Ultrasonic Nebulizers
      - 11.1.5.3 Mesh Nebulizers
  - 11.2 Middle East and Africa Respiratory Inhalers Market (2017-2032) by Type
    - 11.2.1 Conventional Inhalers
    - 11.2.2 Smart Inhalers
  - 11.3 Middle East and Africa Respiratory Inhalers Market (2017-2032) by Country
    - 11.3.1 Saudi Arabia
    - 11.3.2 United Arab Emirates
    - 11.3.3 Nigeria
    - 11.3.4 South Africa
    - 11.3.5 Others
- 12 Regulatory Framework
  - 12.1 Regulatory Overview
    - 12.1.1 US FDA
    - 12.1.2 EU EMA
    - 12.1.3 INDIA CDSCO
    - 12.1.4 JAPAN PMDA
    - 12.1.5 Others
- 13 Patent Analysis
  - 13.1 Analysis by Type of Patent
  - 13.2 Analysis by Publication year

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
  - 14.1 Analysis by Year
  - 14.2 Analysis by Amount Awarded
  - 14.3 Analysis by Issuing Authority
  - 14.4 Analysis by Grant Application
  - 14.5 Analysis by Funding Institute
  - 14.6 Analysis by Departments
  - 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
  - 15.1 Analysis by Funding Instances
  - 15.2 Analysis by Type of Funding
  - 15.3 Analysis by Funding Amount
  - 15.4 Analysis by Leading Players
  - 15.5 Analysis by Leading Investors
  - 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
  - 16.1 Analysis by Partnership Instances
  - 16.2 Analysis by Type of Partnership
  - 16.3 Analysis by Leading Players
  - 16.4 Analysis by Geography
- 17 Supplier Landscape
  - 17.1 Novartis AG
    - 17.1.1 Financial Analysis
    - 17.1.2 Product Portfolio
    - 17.1.3 Demographic Reach and Achievements
    - 17.1.4 Mergers and Acquisitions
    - 17.1.5 Certifications
  - 17.2 AstraZeneca
    - 17.2.1 Financial Analysis
    - 17.2.2 Product Portfolio
    - 17.2.3 Demographic Reach and Achievements
    - 17.2.4 Mergers and Acquisitions
    - 17.2.5 Certifications
  - 17.3 GSK plc
    - 17.3.1 Financial Analysis
    - 17.3.2 Product Portfolio
    - 17.3.3 Demographic Reach and Achievements
    - 17.3.4 Mergers and Acquisitions
    - 17.3.5 Certifications
  - 17.4 Chiesi Farmaceutici SpA
    - 17.4.1 Financial Analysis
    - 17.4.2 Product Portfolio

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Lupin
  - 17.5.1 Financial Analysis
  - 17.5.2 Product Portfolio
  - 17.5.3 Demographic Reach and Achievements
  - 17.5.4 Mergers and Acquisitions
  - 17.5.5 Certifications
- 17.6 Teva Pharmaceutical Industries Ltd
  - 17.6.1 Financial Analysis
  - 17.6.2 Product Portfolio
  - 17.6.3 Demographic Reach and Achievements
  - 17.6.4 Mergers and Acquisitions
  - 17.6.5 Certifications
- 17.7 OMRON Corporation
  - 17.7.1 Financial Analysis
  - 17.7.2 Product Portfolio
  - 17.7.3 Demographic Reach and Achievements
  - 17.7.4 Mergers and Acquisitions
  - 17.7.5 Certifications
- 17.8 Koninklijke Philips N.V.
  - 17.8.1 Financial Analysis
  - 17.8.2 Product Portfolio
  - 17.8.3 Demographic Reach and Achievements
  - 17.8.4 Mergers and Acquisitions
  - 17.8.5 Certifications
- 17.9 PARI GmbH
  - 17.9.1 Financial Analysis
  - 17.9.2 Product Portfolio
  - 17.9.3 Demographic Reach and Achievements
  - 17.9.4 Mergers and Acquisitions
  - 17.9.5 Certifications
- 17.10 Boehringer Ingelheim International GmbH
  - 17.10.1 Financial Analysis
  - 17.10.2 Product Portfolio
  - 17.10.3 Demographic Reach and Achievements
  - 17.10.4 Mergers and Acquisitions
  - 17.10.5 Certifications
- 17.11 GLENMARK PHARMACEUTICALS LTD
  - 17.11.1 Financial Analysis
  - 17.11.2 Product Portfolio
  - 17.11.3 Demographic Reach and Achievements
  - 17.11.4 Mergers and Acquisitions
  - 17.11.5 Certifications
- 17.12 Presspart Verwaltungs GmbH
  - 17.12.1 Financial Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- 17.13 Rossmax International Ltd
  - 17.13.1 Financial Analysis
  - 17.13.2 Product Portfolio
  - 17.13.3 Demographic Reach and Achievements
  - 17.13.4 Mergers and Acquisitions
  - 17.13.5 Certifications
- 17.14 HELTMAN Medikal A.S.
  - 17.14.1 Financial Analysis
  - 17.14.2 Product Portfolio
  - 17.14.3 Demographic Reach and Achievements
  - 17.14.4 Mergers and Acquisitions
  - 17.14.5 Certifications
- 17.15 Microlife Corporation
  - 17.15.1 Financial Analysis
  - 17.15.2 Product Portfolio
  - 17.15.3 Demographic Reach and Achievements
  - 17.15.4 Mergers and Acquisitions
  - 17.15.5 Certifications

List not exhaustive

- 18 Global Respiratory Inhalers Market - Distribution Model (Additional Insight)
  - 18.1 Overview
  - 18.2 Potential Distributors
  - 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
  - 20.1 Very Small Companies
  - 20.2 Small Companies
  - 20.3 Mid-Sized Companies
  - 20.4 Large Companies
  - 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
  - 21.1 Government Funded
  - 21.2 Private Insurance
  - 21.3 Out-of-Pocket

\*Additional insights provided are customisable as per client requirements.

\* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## Global Respiratory Inhalers Market Report and Forecast 2024-2032

Market Report (7 Days) | 2024-04-19 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to [support@scotts-international.com](mailto:support@scotts-international.com)

### ORDER FORM:

Select license	License	Price
	Single User License	\$4999.00
	Five User License	\$5999.00
	Corporate License	\$6999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact [support@scotts-international.com](mailto:support@scotts-international.com) or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-09"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)